30th Mar 2016 08:34
LONDON (Alliance News) - Healthcare company PureTech Health PLC on Wednesday said its Vedanta Biosciences subsidiary has signed a licensing agreement with Japanese research institute RIKEN, the University of Tokyo and Azabu University.
Vedanta is focused on developing new therapies designed to modulate the human microbiome.
The new technology platform which will be created under the agreement will involve immune-boosting microbes isolated from the human gut and may have clinical applications in infectious disease, vaccines and immuno-oncology, PureTech said.
"Vedanta's licence agreement strengthens and broadens Vedanta's platform and leadership in human microbiome-host immune interactions. With this new technology, we can now potentially activate immune cells when needed, along with Vedanta's existing technology which is designed to supress overactive immune responses," said PureTech Chief Executive Daphne Zohar.
PureTech shares were down 0.2% to 151.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech